Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes

CompletedOBSERVATIONAL

Enrollment

243

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

biphasic insulin aspart 30

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Trial Locations (2)

Novo Nordisk Investigational Site, Rud

Novo Nordisk Investigational Site, Farsta